Sofosbuvir and Ledipasvir

DRUG4 trials

Sponsors

Tanta University, National Taiwan University Hospital, Ain Shams University, Assiut University

Conditions

Beta Thalassemia MajorCOVIDHCV InfectionHepatitis CRenal DiseaseViral Hepatitis C

Phase 3

PK of SOF/LED in HCV - Infected Adolescents With Haematological Disorders

Ain Shams UniversityBeta Thalassemia Major, HCV Infection

Start: 2018-06-11End: 2023-12-31Target: 24Updated: 2023-03-06

Phase 4

Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection

CompletedNCT02992457

Tanta UniversityHepatitis C

Start: 2015-01-31End: 2019-12-31Updated: 2023-08-25

Sofosbuvir/Ledipasvir and Nitazoxanide for Treatment of COVID-19

CompletedNCT04498936

Assiut UniversityCOVID

Start: 2020-07-15End: 2020-10-30Updated: 2020-11-12

Unknown Phase

eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs

CompletedNCT04047680

National Taiwan University HospitalHepatitis C, Renal Disease, Viral Hepatitis C

Start: 2015-02-28End: 2019-06-30Updated: 2019-08-08

Related Papers

Favipiravir and/or nitazoxanide: a randomized, double-blind, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE)

Trials2022-07-227 citations

Nitazoxanide superiority to placebo to treat moderate COVID-19 - A Pilot prove of concept randomized double-blind clinical trial.

2021-06-2749 citations

Beta-thalassemia major alters sofosbuvir/ledipasvir exposure in Hepatitis C virus infected adolescent patients.

2021-06-263 citations

High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life experience.

2020-04-305 citations

Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals.

2019-11-2933 citations

Efficacy and safety of sofosbuvir&ndash;ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection

Infection and Drug Resistance2018-02-2840 citations